Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Zydus Lifesciences Limited Press Release Jan 16 2023

· Issued by Zydus Lifesciences Limited via NSE India

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release regarding its tentative approval from the USFDA for Levomilnacipran Extended-Release Capsules. The approval allows Zydus Pharmaceuticals (USA) Inc. to market the drug, which is indicated for treating Major Depressive Disorder in adults. The capsules will be manufactured at the company's facility in Moraiya, Ahmedabad, India.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 16, 2023, titled "Zydus receives tentative approval from the USFDA forLevomilnacipran Extended-Release Capsules".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases